By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ovid Therapeutics 

205 East 42nd Street

New York  New York   10017  U.S.A.
Phone: 212-776-4381 Fax: n/a


Key Statistics

Ownership: Public

Web Site: Ovid
Symbol: OVID


Company News
Ovid (OVID) To Be Added To Russell 2000, 3000 And Microcap Indexes 6/23/2017 8:12:28 AM
New York's Ovid (OVID) Raises $75 Million In IPO Debut 5/5/2017 7:20:32 AM
It's Official: Ovid CEO Just Filed for $86 Million IPO 4/12/2017 6:22:59 AM
Ovid Announces Initiation Of Phase I Clinical Trial Of OV101 For Adolescents With Angelman Syndrome Or Fragile X Syndrome 4/10/2017 10:54:43 AM
Ovid And NeuroPointDx Announce Collaboration To Identify Biomarkers For Angelman Syndrome 2/9/2017 6:36:16 AM
Ovid Release: Company Names Jacqueline A. French, M.D., To Scientific Advisory Board 1/20/2017 10:07:58 AM
Tiny Ovid Inks a Unique Rare Disease Deal With Drug Giant Takeda (TKPYY) 1/18/2017 5:39:12 AM
Ovid Receives Orphan Drug Designation From The FDA For OV101 For The Treatment Of Patients With Angelman Syndrome 9/8/2016 11:22:43 AM
Ovid Announces Participation In Two Upcoming Investor Conferences 9/1/2016 10:53:35 AM
Ovid Expands Leadership Team And Scientific Advisory Board 4/13/2016 11:29:29 AM